112 related articles for article (PubMed ID: 476583)
21. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Rezvani H; Haghighi S; Ghadyani M; Attarian H
Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Vlamis V; Schwartz M; Fossa SD
J Clin Oncol; 1993 Apr; 11(4):607-15. PubMed ID: 7683043
[TBL] [Abstract][Full Text] [Related]
23. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
Cipolla BG; Ziade J; Bansard JY; Moulinoux JP; Staerman F; Quemener V; Lobel B; Guillé F
Cancer; 1996 Sep; 78(5):1055-65. PubMed ID: 8780544
[TBL] [Abstract][Full Text] [Related]
24. N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer.
Brandes LJ; Bracken SP; Ramsey EW
J Clin Oncol; 1995 Jun; 13(6):1398-403. PubMed ID: 7751884
[TBL] [Abstract][Full Text] [Related]
25. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
26. The association between measures of progression and survival in castrate-metastatic prostate cancer.
Scher HI; Warren M; Heller G
Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
Danila DC; Heller G; Gignac GA; Gonzalez-Espinoza R; Anand A; Tanaka E; Lilja H; Schwartz L; Larson S; Fleisher M; Scher HI
Clin Cancer Res; 2007 Dec; 13(23):7053-8. PubMed ID: 18056182
[TBL] [Abstract][Full Text] [Related]
29. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
Wu SL; Jones E; Gulley JL; Arlen PM; Chen CC; Figg WD; Dahut WL
BJU Int; 2007 Mar; 99(3):525-8. PubMed ID: 17155971
[TBL] [Abstract][Full Text] [Related]
30. Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?
Cho Y; Chang JS; Rha KH; Hong SJ; Choi YD; Ham WS; Kim JW; Cho J
PLoS One; 2016; 11(1):e0147191. PubMed ID: 26807740
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy of advanced, hormonally resistant prostatic carcinoma.
Madajewicz S; Catane R; Mittelman A; Wajsman Z; Murphy GP
Oncology; 1980; 37(1):53-6. PubMed ID: 7188644
[TBL] [Abstract][Full Text] [Related]
32. Carcinoma of the prostate with soft tissue or non-regional lymphatic metastases at the time of diagnosis: a review of 47 cases.
Saeter G; Fosså SD; Ous S; Blom GP; Kaalhus O
Br J Urol; 1984 Aug; 56(4):385-90. PubMed ID: 6534426
[TBL] [Abstract][Full Text] [Related]
33. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Sella A; Sternberg C; Kovel S; Yarom N; Skoneczna I
BJU Int; 2007 Sep; 100(3):533-5. PubMed ID: 17559560
[TBL] [Abstract][Full Text] [Related]
34. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
35. Vincristine, bleomycin, methotrexate, 5-fluorouracil, and prednisone in metastatic, hormonally unresponsive prostatic adenocarcinoma.
Paulson DF; Walker RA; Berry WR; Cox EB; Hinshaw W
Urology; 1981 May; 17(5):443-5. PubMed ID: 6165129
[TBL] [Abstract][Full Text] [Related]
36. Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
Afriansyah A; Hamid ARA; Mochtar CA; Umbas R
Int J Urol; 2019 Jan; 26(1):83-89. PubMed ID: 30269369
[TBL] [Abstract][Full Text] [Related]
37. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
Inoue T; Segawa T; Kamba T; Yoshimura K; Nakamura E; Nishiyama H; Ito N; Kamoto T; Habuchi T; Ogawa O
Urology; 2009 May; 73(5):1104-9. PubMed ID: 19394511
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.
Petrylak DP; Scher HI; Li Z; Myers CE; Geller NL
Cancer; 1992 Dec; 70(12):2870-8. PubMed ID: 1451069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
